Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Lu-PSMA-617

Lu-PSMA-617

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28%
Oncology RCT
Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28% New Treatment Options for Men with Advanced Prostate Cancer
This Phase 3 randomized controlled trial of 1144 patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate …
A large study shows that adding a specific radioactive treatment to standard hormone therapy can help slow cancer growth.
Aug 31, 2026
PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617
Urology Meta-analysis
PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617 PSMA PET scan numbers may help predict Lu-PSMA therapy response in prostate cancer
Meta-analysis of 23 studies shows PSMA PET parameters, especially tumor volume, predict survival in mCRPC patients treated with Lu-PSMA-617.
A meta-analysis of 23 studies suggests certain PSMA PET scan measurements might help predict how patients with metastatic prostate cancer re…
Jun 3, 2026